Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theophylline is a methylxanthine derivative and bronchodilator used to manage symptoms of asthma and chronic obstructive pulmonary disease (COPD), as well as other lung conditions characterized by reversible airflow obstruction. It works primarily by relaxing bronchial smooth muscle to improve airflow. Mechanistically it acts as a nonselective phosphodiesterase inhibitor (leading to increased intracellular cAMP), an adenosine receptor antagonist (blocking bronchoconstrictive effects of adenosine), and a histone deacetylase activator. The drug also has mild diuretic properties and central nervous system stimulant effects. The primary indications are asthma and COPD; it is considered a second-line agent due to its narrow therapeutic window and potential for toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on theophylline.